Varian Associates proceeds with company split
Varian Associates shareholders last month voted to approve a proposal to split the company into three separate businesses. The Palo Alto, CA, firm’s instruments and semiconductor equipment concerns will be spun off into separate companies, while the
Varian Associates shareholders last month voted to approve a proposal to split the company into three separate businesses. The Palo Alto, CA, firms instruments and semiconductor equipment concerns will be spun off into separate companies, while the remaining healthcare unit will be renamed Varian Medical Systems.
Varians board of directors proposed the split in August in an effort to focus each of its disparate businesses (SCAN 9/2/99). On Feb. 16, the company received notice from the Internal Revenue Service that the agency will allow the split to be treated as a tax-free transaction for shareholders. Two days later, Varians stockholders voted for the split.
Varian Medical Systems will continue to be listed on the New York Stock Exchange and will keep the symbol VAR. The instruments company will be called Varian, and the semiconductor business will be called Varian Semiconductor Equipment Associates.
In other news, Varian X-Ray Tube Products has introduced a series of high-performance CT x-ray tubes. The Quantum Series CT tube is based on an integral housing technology that consolidates three commonly used components of the tube: the element that generates the x-rays, the lead-lined container, and the device that helps cool the tube. Varian plans to market the tubes for use in low-cost CT systems and will begin shipping them early this year.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
